Evidence map›Paper›PMID 42258084›Full record

ArticleBiochemical genetics2026

Epirubicin-Induced Upregulation of miR-143-3p and miR-145 Enhances Cytotoxicity in MCF-7, MDA-MB-231, and BT-474 Breast Cancer Cell Lines.

Morteza Rajabi, Niki Ghambari Mohammadi, Mahsa Mombeyni, Roudabeh Behzadi Andouhjerdi

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Morteza RajabiDepartment of Biology, Faculty of Basic Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran.ORCID http://orcid.org/0009-0008-9669-7397
Niki Ghambari MohammadiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-6664-4798
Mahsa MombeyniThalasemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.ORCID http://orcid.org/0000-0003-1083-8627
Roudabeh Behzadi AndouhjerdiDepartment of Biology, Faculty of Basic Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran. Roudabehbehzadi2025@gmail.com.ORCID http://orcid.org/0000-0003-0961-6672

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance poses a significant challenge to effective breast cancer chemotherapy. This study investigated the regulatory effects of Epirubicin on miR-143-3p and miR-145 expression in BT-474, MCF-7, and MDA-MB-231 breast cancer cell lines. These miRNAs, known as tumor suppressors, are often downregulated in breast carcinoma, correlating with poorer prognosis. Cells were treated with Epirubicin, and miR-143-3p and miR-145 expression was quantified via qRT-PCR. Epirubicin IC

Indexed as

Antibiotics, AntineoplasticBreast NeoplasmsEpirubicinGene Expression Regulation, NeoplasticMicroRNAsUp-RegulationCell Line, TumorFemaleHumansMCF-7 CellsMDA-MB-231 CellsAntibiotics, AntineoplasticEpirubicinMicroRNAsMIRN143 microRNA, humanMIRN145 microRNA, humanApoptosisBreast neoplasmsEpirubicinMicroRNAsMiR-143-3pMiR-145

Identifiers

PMID42258084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.